VALGANCICLOVIR HYDROCHLORIDE

Search structure
Trade Names:
Synonyms:
Status: Approved (2001)
Entry Type: Small molecule
Molecule Category: Salt Prodrug
UNII: 4P3T9QF9NZ
Parent Compound: VALGANCICLOVIR

Structure
InChI Key ZORWARFPXPVJLW-MTFPJWTKSA-N
Smile CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21.Cl
InChI
InChI=1S/C14H22N6O5.ClH/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22;/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22);1H/t8?,9-;/m0./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C14H23ClN6O5
Molecular Weight 390.83
AlogP -1.44
Hydrogen Bond Acceptor 10.0
Hydrogen Bond Donor 4.0
Number of Rotational Bond 8.0
Polar Surface Area 171.37
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 25.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Human herpesvirus 1 DNA polymerase inhibitor DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Uveitis, Anterior 2 D014606 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Infections and infestations
15.94
General disorders and administration site conditions
11.65
Injury, poisoning and procedural complications
11.5
Blood and lymphatic system disorders
9.85
Gastrointestinal disorders
7.38
Nervous system disorders
5.45
Investigations
4.74
Respiratory, thoracic and mediastinal disorders
4.45
Renal and urinary disorders
3.39
Metabolism and nutrition disorders
3.34
Vascular disorders
3.1
Musculoskeletal and connective tissue disorders
2.94
Immune system disorders
2.71
Skin and subcutaneous tissue disorders
2.62

Cross References

Resources Reference
ChEMBL CHEMBL1200454
EPA CompTox DTXSID9046784
FDA SRS 4P3T9QF9NZ
PubChem 135413534
SureChEMBL SCHEMBL23225
CONTENTS